ClinicalTrials.Veeva

Menu

Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients

F

Federal University of Minas Gerais

Status

Completed

Conditions

Fibromyalgia

Treatments

Dietary Supplement: Rice protein
Dietary Supplement: Gluten

Study type

Interventional

Funder types

Other

Identifiers

NCT03129906
48529415.8.0000.5149

Details and patient eligibility

About

The aim of this study is to evaluate the impact of gluten-free diets on symptoms and inflammatory markers in individuals with previous diagnosis of fibromyalgia (FM), as well as to identify the presence of non-celiac gluten sensitivity (NCSG) in individuals with FM. Patients with FM diagnosis will be kept on a gluten-free diet for a 10 weeks. In the 7th week, they will receive placebo capsules for 7 days and after washout, capsules containing gluten for another 7 days. A questionnaire based on Salerno protocol will be applied to evaluate the presence of NCGS in the beginning, 8th week and 10 week.

Full description

Fibromyalgia (FM) is a chronic and widespread pain condition, usually accompanied by several associated symptoms such as fatigue, sleep disorder, headache, irritable bowel syndrome and mood disorders. Recent studies point to the possibility of gluten protein having a role in the development of FM symptoms in a subgroup of patients. Fourteen patients with FM diagnosis will be kept on a diet restrict in gluten-free foods for a period 10 weeks. At the 7th week they received rice protein isolate capsules (placebo) for 7 days, followed by a 3-day wash-out and a new challenge with capsules containing 8 g/day of gluten (corresponding to 6,3g gluten protein) for another 7 days. In the initial period, at 8th week (final of placebo period) and after challenge with gluten (10th week), blood will be collected for analysis of inflammatory markers. Questionnaires will be carried out to evaluate the quantity and severity of FM symptoms and the impact of FM on daily routine. Inflammatory markers (IL-1bera, IL-6 and IL-10) will be evaluated in the blood. In the challenger period (gluten or placebo) questionnaires will be carried out to evaluate the quantity and severity of symptoms related to fibromyalgia and the impact of fibromyalgia on a daily basis. In addition, a questionnaire based on Salerno protocol was applied to evaluate the presence of NCGS.

Enrollment

26 patients

Sex

Female

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

• Women between 18 and 65 years of age with prior clinical diagnosis of FM, according to the American College of Rheumatology criteria of 2010

Exclusion criteria

  • Subjects diagnosed with positive serology for celiac disease or allergy to wheat
  • Subjects diagnosed with autoimmune diseases
  • Subjects with diseases that are not part of the comorbidities associated with FM and t hat could influence the results of the study
  • Pregnant or lactating women

Trial design

Primary purpose

Basic Science

Allocation

Non-Randomized

Interventional model

Sequential Assignment

Masking

Single Blind

26 participants in 2 patient groups, including a placebo group

Gluten
Active Comparator group
Description:
Capsules containing 8 g/day of gluten (6,3g of protein) were blindly administered for 7 days
Treatment:
Dietary Supplement: Gluten
Rice protein
Placebo Comparator group
Description:
Capsules containing 6,4 g/day of rice protein were blindly administered for 7 days
Treatment:
Dietary Supplement: Rice protein

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems